A

Artrya Ltd
ASX:AYA

Watchlist Manager
Artrya Ltd
ASX:AYA
Watchlist
Price: 3.45 AUD -1.43% Market Closed
Market Cap: 545.4m AUD

Artrya Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Artrya Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
A
Artrya Ltd
ASX:AYA
Cash & Cash Equivalents
AU$11.3m
CAGR 3-Years
-9%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Mach7 Technologies Ltd
ASX:M7T
Cash & Cash Equivalents
AU$23.1m
CAGR 3-Years
-4%
CAGR 5-Years
-14%
CAGR 10-Years
24%
4DMedical Ltd
ASX:4DX
Cash & Cash Equivalents
AU$6.9m
CAGR 3-Years
-49%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
CogState Ltd
ASX:CGS
Cash & Cash Equivalents
$35.6m
CAGR 3-Years
5%
CAGR 5-Years
28%
CAGR 10-Years
24%
Pro Medicus Ltd
ASX:PME
Cash & Cash Equivalents
AU$174.5m
CAGR 3-Years
40%
CAGR 5-Years
43%
CAGR 10-Years
30%
Alcidion Group Ltd
ASX:ALC
Cash & Cash Equivalents
AU$17.7m
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
17%
No Stocks Found

Artrya Ltd
Glance View

Market Cap
545.4m AUD
Industry
Health Care

Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.

AYA Intrinsic Value
2.66 AUD
Overvaluation 23%
Intrinsic Value
Price
A

See Also

What is Artrya Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
11.3m AUD

Based on the financial report for Jun 30, 2025, Artrya Ltd's Cash & Cash Equivalents amounts to 11.3m AUD.

What is Artrya Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
38%

Over the last year, the Cash & Cash Equivalents growth was 59%. The average annual Cash & Cash Equivalents growth rates for Artrya Ltd have been -9% over the past three years , 38% over the past five years .

Back to Top